The FDA issued a warning letter to Purolea Cosmetics Lab citing, for the first time, inappropriate use of artificial intelligence in pharmaceutical manufacturing as a compliance deficiency. Investigators found the company used AI to generate drug specifications, standard operating procedures, and production records that were then used in manufacturing without adequate review by its quality unit, and the AI-generated documentation omitted required process validation steps. The company has since ceased its drug production.